Stockwinners Market Radar for January 17, 2025 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

20:12 EST Cathie Wood's ARK Investment bought 147K shares of Crispr Therapeutics today

17:32 EST AstraZeneca's Datroway approved in U.S. for HER2-negative breast cancer patients - The company states: "Datroway, or Dato-DXd, has been approved in the US for the treatment of adult patients with unresectable or metastatic hormone receptor HR-positive, HER2-negative breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease. The approval by the US Food and Drug Administration was based on results from the TROPION-Breast01 Phase III trial. In TROPION-Breast01, Datroway significantly reduced the risk of disease progression or death by 37% compared to investigator's choice of chemotherapy in patients with HR-positive, HER2-negative metastatic breast cancer as assessed by blinded independent central review. Median progression-free survival was 6.9 months in patients treated with Datroway versus 4.9 months with chemotherapy. The safety profile of Datroway was consistent with the known profile of this medicine with no new safety concerns identified. In the Datroway arm, the interstitial lung disease rate was 4.2% and the majority of events were low grade." Reference Link

17:11 EST GeoPark announces 2025 Work Program to deliver increasing value - GeoPark Limited announced its 2025 Work Program, approved by its board. The program is "designed to deliver increasing value to its shareholders through disciplined capital allocation, operational excellence, and sustainable growth." The program integrates and responds to the following key principles of GeoPark's "North Star" strategy: Highly profitable, dependable and sustainable, with more than $400M of annual EBITDA generation; Focused on growth through big assets, big basins and big plays, with a diversified footprint in Colombia, Argentina, and Brazil; Near term performance, long term vision and targets, targeting 70,000 boepd mid-term (2028), 100,000 boepd long-term (2030); Financial flexibility and stewardship, with net debt to EBITDA 1.5-2.1x at $70-80/bbl, strong cashflow generation of $120M-180M ending cash; and Competitive shareholder returns while driving sustainable growth, by maintaining an annual dividend of $30M.

17:10 EST Lockheed Martin awarded $280.4M U.S. Navy contract - Lockheed Martin is awarded a $280,418,928 cost-plus-fixed-fee, cost-plus-incentive-fee, and cost type modification to previously awarded contract N00024-23-C-5101 for combat systems engineering efforts of the planned modernization and new combat system capabilities selection for international partner Canadian Royal Navy ships operating AEGIS.

17:03 EST Bank of Montreal says TSX approves normal course issuer bid for 20M shares - Bank of Montreal announced that it has received approvals from the Toronto Stock Exchange and the Office of the Superintendent of Financial Institutions Canada to proceed with its previously-announced normal course issuer bid to purchase, for cancellation, up to 20M of its common shares, commencing January 22, 2025, and ending no later than January 21, 2026.

16:33 EST Lithium Argentina shareholders approve corporate migration to Switzerland - Lithium Americas is pleased to announce that the company's shareholders approved its plan to change its place of incorporation from Canada to Switzerland at its Special Meeting of Shareholders. The Special Meeting saw representation of 39.78% of the total shares outstanding being voted. The arrangement resolution to approve the Corporate Migration to Switzerland received overwhelming support with 99.23% approval from all voting shareholders.

16:31 EST Arrowhead says FDA accepts NDA for investigational plozasiran - Arrowhead Pharmaceuticals announced that the U.S. FDA has accepted the New Drug Application for investigational plozasiran for the treatment of familial chylomicronemia syndrome, a severe and rare genetic disease. The FDA provided a Prescription Drug User Fee Act action date of November 18, and indicated it is not currently planning to hold an advisory committee meeting. Arrowhead also intends to submit applications for approval of investigational plozasiran for the treatment of patients with FCS to additional regulatory authorities in 2025.

16:23 EST Comcast says 'Wicked' surpasses $700M at global box office - Comcast said that Universal Pictures' film "Wicked" has crossed the $700M mark at the global box office. Of the total, $240.4M comes from the international box office, while $460.6M is generated domestically. This milestone was achieved even as the film transitioned to Premium VOD on Dec. 31, 2024 where it became the best first week Universal has seen for any theatrical title with a premium release at $70M in one week. Starring Cynthia Erivo and Ariana Grande, "Wicked" ended 2024 as Universal's second-highest-grossing film of the year globally. It also became the highest-grossing non-sequel of 2024 and claimed the title of the all-time top-grossing stage musical adaptation, surpassing Universal's own "Mamma Mia!." "Wicked: For Good," the film's second act opens in theaters a year after the original, on November 21, 2025. Reference Link

16:17 EST Starbucks CEO sees job eliminations, smaller support teams moving forward - Starbucks CEO Brian Niccol said in a message to staff, "In September, we outlined our plan to revitalize Starbucks by focusing on what has always set us apart: a welcoming coffeehouse where people gather and where we serve the finest coffee, handcrafted by our skilled baristas. Since then, we have been enhancing the in-store experience with the return of the condiment bar, writing on cups, more ceramic mugs and a revised code of conduct. We've shifted our marketing from discounts to highlighting our brand story and coffee leadership. We've taken steps on pricing transparency by removing the non-dairy milk upcharge. We've set a goal of a four-minute wait time in cafes and have provided additional coverage hours in over 3,000 stores. We've doubled paid parental leave for our U.S. retail teams and aim to promote internally for 90% of retail leadership roles in three years. We have much more work to do but I'm pleased with the progress we've made and appreciate how everyone has rallied around the plan. Our initial work has - rightly - focused on our U.S. and Canada stores and the store experience. However, as we look to transform our business globally, we also need to examine the role, structure and size of our support teams around the world. Across our support teams, we have many talented partners with deep expertise and a strong, skilled team that is driving impact for our customers, partners and business every day. As I've spent time working with teams across the business and observed how we work, it's also clear that we have some opportunities to operate more efficiently. Additional opportunities include: Increased ownership and accountability: We need to ensure all our work has a clear owner, who can make decisions, and who is accountable for achieving the goals. This will help us move faster. Clear priorities and reduced complexity: Our Back to Starbucks plan is the priority, and we need to stay focused, reduce complexity and remove conflicting goals. Better integration: We need to reduce silos and duplication of effort. Our size and structure can slow us down, with too many layers, managers of small teams and roles focused primarily on coordinating work. We need to meaningfully change how our support teams are organized and how we work, making sure that we have the capacity and capabilities to deliver on Back to Starbucks, and are prioritizing the areas that have the biggest impact on the experience in our stores. We have recently begun the work to define the support organization for the future. We are approaching this work thoughtfully, but it will involve difficult decisions and choices. I expect that, unfortunately, we will have job eliminations and smaller support teams moving forward. This work will not affect our in-store teams or the investments we are making in store hours. We will communicate changes by early March. I do not take these decisions lightly, and I appreciate that this will create uncertainty and concern between now and then. I wanted to be transparent about our progress and our plans and ensure that you hear about this work directly from me."

16:07 EST Chewy CEO Singh sells 114,130 class A shares - In a regulatory filing, Chewy CEO Sumit Singh disclosed the sale of 114,130 class A shares of the company on January 15 at a price of $37.696 per share.

15:15 EST Dogness Intl Corp Class A trading resumes

15:07 EST Opko, BioReference to pay over $700K to resolve False Claims Act allegations - BioReference Health LLC, formerly known as BioReference Laboratories Inc., and OPKO Health Inc. have agreed to pay $704,349 to resolve alleged violations of the False Claims Act arising from BioReference's submission of claims for laboratory tests that had not been ordered by a patient's provider. OPKO is a Delaware Corporation. BioReference, a subsidiary of OPKO, is headquartered in New Jersey and is one of the largest clinical laboratories in the United States. The United States alleged that BioReference and OPKO knowingly submitted false claims to federal healthcare programs for complete blood count (CBC) with automated white blood cell differential laboratory tests that were not medically necessary. Specifically, the United States alleged that, from Jan. 1, 2012, until March 1, 2023, BioReference and OPKO routinely performed more expensive CBC with WBC differential tests when, in fact, medical providers had ordered less expensive CBC with no WBC differential tests, and then billed federal healthcare programs for the more expensive and medically unnecessary tests. Reference Link

15:05 EST Dogness Intl Corp Class A trading halted, volatility trading pause

13:36 EST Kroger acquires land in Little Elm, Texas for new store - Davidson Bogel Real Estate announced its successful representation of Kroger in the acquisition of a 14-acre property in Little Elm, Texas from local investment firm Dollar-Flowers Realty Partners. The 14-acre site, located at US 380 and FM 2931, in one of the fastest-growing communities in North Texas, allows for Kroger to enhance its retail presence and serve the expanding population of Little Elm and surrounding areas with quality grocery offerings. Edward Bogel, Ryan Turner, and David Davidson Jr. of Davidson Bogel represented Kroger in the transaction. Dollar-Flowers was represented internally by Stewart Flowers. HEB owns the land directly west of the future Target but has not released timing for developing the land.

13:19 EST Mercurity Fintech Holdings trading resumes

13:12 EST GlobalFoundries up 8% to $44.11 after Bloomberg report on semi space

13:01 EST Baker Hughes reports U.S. rig count down 4 to 580 rigs

12:44 EST Tennessee announces settlement with BlackRock over ESG practices - Tennessee Attorney General Jonathan Skrmetti announced a settlement with BlackRock, resolving allegations that the company misled consumers regarding the role of environmental, social, and governance factors in its investment practices. The settlement concludes a lawsuit filed by the State of Tennessee under the Tennessee Consumer Protection Act. BlackRock will increase its disclosure of proxy voting practices and implement compliance measures as part of the settlement. Reference Link

12:00 EST ProShares UltraShort Bloomberg Natural Gas rises 11.3% - ProShares UltraShort Bloomberg Natural Gas is up 11.3%, or $3.19 to $31.31.

12:00 EST Nuscale Power rises 13.5% - Nuscale Power is up 13.5%, or $2.73 to $23.01.

12:00 EST D-Wave Quantum falls -6.6% - D-Wave Quantum is down -6.6%, or -39c to $5.42.

11:29 EST Park Aerospace corrects 'incorrect reporting' about Q3 call and presentation - Park Aerospace reports "incorrect reporting" by independent transcription services and news articles relating to the company's Q3 investor conference call and investor presentation which occurred on January 14. The company states: "The company's fiscal year 2025 third quarter investor presentation made several references to the 'requalification', by one of the company's customers, of products supplied by one of the company's suppliers. In addition, during the third quarter investor conference call, Brian E. Shore, the company's Chairman and CEO, made several references to the 'requalification' or 'requal' of the supplier's products. Unfortunately, several independent computer or AI generated transcription services incorrectly reported the references during the investor conference call to the 'requalification' or 'requal' of the supplier's products as the 'recall' of its products. In addition, several news articles written about the company's third quarter investor conference call incorrectly reported that there was a 'recall' of the company's supplier's products. Apparently, the authors of these articles relied on the incorrect computer or AI generated transcriptions rather than the company's investor call presentation and the actual comments made by Mr. Shore during the investor conference call. There was no reference, in the company's third quarter investor presentation, to any recall of any products, and the term 'recall' was not used in the presentation. There was no reference, during the third quarter investor conference call, to any recall of any products. The term 'recall' was never used during the investor call. The company is not responsible for the accuracy of independent computer or AI generated transcriptions of, or independent reports about, the company's investor conference calls, and the company has no obligation to correct inaccuracies in such independently generated transcriptions or independent reports now or in the future. However, while a 'requalification' is a fairly common and benign event in the aerospace industry, a 'recall' has potentially very negative implications. Accordingly, the company has elected, in this instance, to correct the incorrect transcriptions and articles. As stated, there was no reference in the company's third quarter investor conference call or investor presentation to any 'recall' of any suppliers' products, and the company is not aware of any such recall."

11:20 EST Trump says his decision on TikTok coming 'in not too distant future' - President-elect Donald Trump stated in a post to Truth Social: "The Supreme Court decision was expected, and everyone must respect it. My decision on TikTok will be made in the not too distant future, but I must have time to review the situation. Stay tuned!" Reference Link

11:08 EST PepsiCo sued by FTC for rigging soft drink competition - The Federal Trade Commission sued PepsiCo alleging that the second-largest food company in the world has engaged in illegal price discrimination by providing one customer-a large, big box retailer-with unfair pricing advantages, while raising prices for competing retailers and customers. For years, Pepsi has disadvantaged retailers-ranging from large grocery chains to independent, local convenience stores-who compete with one of its largest big box customers by consistently giving that favored large, big box retailer customer key benefits and advantages, such as promotional payments, while denying those same benefits to its competitors, the FTC's complaint alleges. "When firms like Pepsi give massive retailers a leg up, it tilts the playing field against small firms and ultimately inflates prices for American consumers," said FTC Chair Lina M. Khan. "The FTC's action will help ensure all grocers and other businesses-no matter the size-can get a fair shake and compete on the merits of their skill, efficiency, and talent." Reference Link

10:34 EST Webster Financial sees FY25 NII $2.45B-$2.50B - Assumes 2 fed funds rate cuts beginning in March. Sees FY25 adjusted non-interest income $370M-$390M. Expects adjusted expenses to be in range of $1.39B-$1.41B and efficiency ratio in range of 45%-47%. Sees deposit growth 4%-5%. Sees common equity tier 1 ratio near-term target 11% and long-term target 10.5%. Comments taken from Q4 earnings conference call presentation slides.

10:29 EST Huntington Bancshares sees FY25 NII up 4%-5% - Sees FY25 average loans up 5%-7%, with average deposits up 3%-5%. Sees FY25 noninterest income up 4%-6% and noninterest expense up 3.5%-4.5%. Sees FY25 net chargeoffs 25-35bps.

10:16 EST GeoPark trading resumes

10:10 EST Anterix jumps after FCC proposes framework for 900 MHz broadband - The shares are up 5% to $29.17 in morning trading.

10:03 EST Peoples Bancorp announces special dividend of 16c per share - Peoples Bancorp of North Carolina announced the declaration of a special cash dividend in the amount of 16c per share. The special cash dividend will be paid on February 14, to shareholders of record on February 3.

10:00 EST United States Natural Gas Fund falls -6.8% - United States Natural Gas Fund is down -6.8%, or -$1.36 to $18.58.

10:00 EST Mytheresa rises 8.0% - Mytheresa is up 8.0%, or 67c to $9.09.

10:00 EST ProShares UltraShort Bloomberg Natural Gas rises 12.5% - ProShares UltraShort Bloomberg Natural Gas is up 12.5%, or $3.52 to $31.64.

09:54 EST Broadway Financial trading resumes

09:49 EST Broadway Financial trading halted, volatility trading pause

09:47 EST Sasol rises 9.7% - Sasol is up 9.7%, or 48c to $5.46.

09:47 EST Direxion Daily Semiconductor Bear 3X Shares falls -5.9% - Direxion Daily Semiconductor Bear 3X Shares is down -5.9%, or -$1.17 to $18.76.

09:47 EST United States Natural Gas Fund falls -7.2% - United States Natural Gas Fund is down -7.2%, or -$1.43 to $18.51.

09:42 EST BurTech Acquisition Corp trading resumes

09:38 EST Trump says spoke to China's Xi Jinping about trade, fentanyl and TikTok - President-elect Donald Trump stated in a post to Truth Social: "I just spoke to Chairman Xi Jinping of China. The call was a very good one for both China and the U.S.A. It is my expectation that we will solve many problems together, and starting immediately. We discussed balancing Trade, Fentanyl, TikTok, and many other subjects. President Xi and I will do everything possible to make the World more peaceful and safe!" Reference Link

09:31 EST Crown Electrokinetics announces exclusive partnership with Electro Scan Inc. - Crown Electrokinetics announced that it has entered into an exclusive partnership with Electro Scan Inc., the developer of cutting-edge lead detection technology. Under this agreement, Crown has secured exclusive rights to deploy Electro Scan's advanced lead detection device, the Swordfish, across 48 U.S. states. This partnership firmly positions Crown's Element 82 as a leader in lead pipe detection solutions. Element 82 is expected to play a significant role in contributing to Crown's expected full year 2025 revenue guidance of $30M-$35M, highlighting the strategic value of this collaboration.

09:30 EST Bausch Health acknowledges XIFAXAN selection for Medicare Negotiation Program - Bausch Health Companies and Salix Pharmaceuticals acknowledged that the Centers for Medicare and Medicaid Services has selected XIFAXAN 550 mg tablets as one of the medicines for the second round of negotiation as part of the Inflation Reduction Act with an initial price applicability in 2027 of the Drug Price Negotiation program. The company said, "We look forward to engaging in open and transparent conversations with CMS, where we will share information on the value that XIFAXAN delivers for the healthcare system in addition to sharing recommendations from The American Association for the Study of Liver Diseases and the European Association for the Study of the Liver who gave XIFAXAN the highest possible recommendation via their practice guidelines. We will continue to be driven by our commitment to patients in advocating for a healthcare environment that supports patient access to critical medications as well as encouraging future innovation."

09:21 EST PepsiCo closes acquisition of Siete Foods - PepsiCo announced that it has closed the acquisition of Garza Food Ventures LLC, dba Siete Foods, for $1.2B.

09:16 EST Terreno Realty sells property in South San Francisco, CA for $8M - Terreno Realty sold an industrial property located in South San Francisco, California on January 16, 2025 for a sale price of approximately $8.0 million. The property consists of one industrial building containing approximately 22,000 square feet on 0.7 acres which is 100% leased to one tenant. The property was purchased by Terreno Realty Corporation on July 10, 2020 for $6.3 million. The unleveraged internal rate of return generated by the investment was 7.5%.

09:13 EST LPL Financial to pay civil penalty of $18M to settle SEC charges - The Securities and Exchange Commission announced charges against broker-dealer and investment adviser LPL Financial for multiple failures related to its anti-money laundering program. To resolve the SEC's charges, LPL agreed to pay a civil penalty of $18M and to implement improvements to its AML policies and procedures. Reference Link

09:11 EST Figs won't pursue STORY3's unsolicited acquisition proposal - In a regulatory filing last night, Figs disclosed that on January 16, the company sent a letter to STORY3 Capital Partners, informing STORY3 that the company's board of directors, including a special committee of independent and disinterested directors with independent financial and legal advisors, after careful consideration, "remains confident in the company's standalone plan and prospects and has decided not to pursue STORY3's unsolicited acquisition proposal." Reference Link

09:08 EST CubeSmart COO Joel Keaton to retire - CubeSmart announced that Joel Keaton, COO, will retire effective April 30, 2025. In connection with Keaton's planned retirement, the company is promoting proven leaders to assume his responsibilities. Following his retirement, Mr. Keaton will serve as a consultant to CubeSmart to ensure a smooth transition. In connection with Joel's retirement, the company announced the following leadership changes: Amy Cross will be promoted to Executive Vice President, Technology, Data Science, and Marketing. Cross currently serves as Senior Vice President, Information Technology and Revenue Management. Cross will report to President and CEO Christopher Marr. Guy Middlebrooks will be promoted to Executive Vice President, Operations. Middlebrooks currently serves as Senior Vice President, Third Party Management. In his new role, he will oversee the Company's field operations organization in addition to third party management and store transitions. Middlebrooks will also report to Marr.

09:05 EST Rackspace appoints Jeffrey Benjamin as independent chairman of the board - Rackspace Technology (RXT) announced Board and executive transitions. The Company also re-affirmed financial guidance for the fourth quarter 2024, as previously provided in a press release issued on November 12, 2024. Jeffrey Benjamin will succeed David Sambur as Independent Chairman of the Board. Benjamin has been on the Rackspace Board since 2016 and chairs the Audit Committee. Benjamin has over 25 years of experience in investment management and has served on the boards of American Airlines Group and Caesars Entertainment Company, among others. Sambur, Partner and Co-Head of Equity at Apollo Global Management (APO), stepped down from the Rackspace Board after nine years of dedicated service. In addition, Vikram Mahidhar will be joining the Rackspace Board. Mahidhar has led the digital, data, and artificial intelligence team at Apollo Global Management as an Operating Partner within the Apollo Portfolio Performance Solutions group since 2021. The company also announced that Brian Lillie, President of Private Cloud, will be moving on from his position to focus on personal commitments. Rackspace CEO Amar Maletira will assume the role of Interim Leader for the Private Cloud business. The Company has initiated a search for Lillie's successor. Lillie is expected to remain with the Company in an advisory capacity until April 5, 2025.

09:03 EST Amgen announces FDA approval of Lumakras in combination with Vectibix - Amgen announced that the U.S. FDA has approved Lumakras in combination with Vectibix for the treatment of adult patients with KRAS G12C-mutated metastatic colorectal cancer, as determined by an FDA-approved test, who have received prior fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy. Approval is based on the pivotal Phase 3 CodeBreaK 300 study, which demonstrated that Lumakras plus Vectibix is the first and only targeted treatment combination for chemorefractory KRAS G12C-mutated mCRC to show superior progression-free survival compared to the investigated standard-of-care.

09:02 EST Wells Fargo advisory firms, Merrill Lynch to pay $60M to settle SEC charges - The Securities and Exchange Commission on Friday announced settled charges against registered investment advisers Wells Fargo Clearing Services LLC (WFC) and Wells Fargo Advisors Financial Network LLC and against Merrill Lynch, Pierce, Fenner & Smith Incorporated (BAC) for failing to adopt and implement written policies and procedures reasonably designed to prevent violations of the Advisers Act and the rules thereunder relating to the firms' cash sweep programs. The firms agreed to settle the SEC's charges and pay $60M in total civil penalties. According to the SEC's orders, Wells Fargo Advisors and Merrill Lynch offered bank deposit sweep programs as the only cash sweep option for most advisory clients and received a significant financial benefit from advisory client cash in the BDSPs. The orders find that these firms or their affiliates set the interest rates offered in the BDSPs and that, during periods of rising interest rates, the yield differential between the BDSPs and other cash sweep alternatives at times grew to almost 4 percent. According to the orders, Wells Fargo Advisors and Merrill Lynch failed to adopt and implement reasonably designed policies and procedures (1) to consider the best interests of clients when evaluating and selecting which cash sweep program options to make available to clients, including during periods of rising interest rates, and (2) concerning the duties of financial advisors in managing client cash in advisory accounts. Without admitting or denying the SEC's findings, Wells Fargo Clearing Services, Wells Fargo Advisors Financial Network, and Merrill Lynch consented to the entry of orders finding that they violated the Advisers Act and ordering them to be censured and to cease and desist from violating the charged provisions. Wells Fargo Clearing Services agreed to pay a civil penalty of $28M; Wells Fargo Advisors Financial Network agreed to pay a civil penalty of $7M; and Merrill Lynch agreed to pay a civil penalty of $25M. Reference Link

08:48 EST Oklo, RPower join forces to accelerate power availability for data centers - Oklo has signed a memorandum of understanding with RPower, a leading provider of onsite prime and backup power solutions, to deploy a phased power model for data centers. This model combines immediate energy deployment using RPower natural gas generators with a transition path to clean, reliable energy from Oklo's Aurora powerhouses, eliminating reliance on diesel generators and supporting scalable, sustainable operations.

08:47 EST Veea, Lynxspring announce collaborative strategic partnership - Veea and Lynxspring announced they have partnered to jointly rollout technologies and solutions that simplify data management, improve operational efficiency, and enable real-time decision-making for building owners and operators. "Lynxspring's 23+ years of experience in OT connectivity, technology development and deployment, integration and interoperability expertise and their ability to complement our technology and solutions through powerful software, hardware and support services make them an ideal partner for our company," said Allen Salmasi, Founder and CEO of Veea. "Integrating the Lynxspring platform with the Veea Edge platform enables us to address a wide range of use cases through combined offerings of our products and services."

08:35 EST SEALSQ announces Common Criteria EAL5+ Certification for MS600X Platform - SEALSQ announced that its MS600X Secure Hardware Platform has been awarded the Common Criteria EAL5+ Certification. The Common Criteria Evaluation Assurance Level is a globally accepted standard for evaluating the security of IT products. The EAL5+ Certification is specifically tailored for products designed to protect high-value assets against sophisticated attacks

08:33 EST Armlogi announces integration of Amazon Shipping into shipping solutions - Armlogi Holding (BTOC) announced the integration of Amazon Shipping (AMZN) into its suite of shipping solutions. This new addition is expected to enhance Armlogi's shipping capabilities, providing customers with more efficient and cost-effective options for parcel delivery. Since its launch last week, Amazon Shipping has already enabled Armlogi to handle thousands of parcels daily.

08:32 EST Air Products board urges shareholders to vote on the white proxy card - Air Products' Board of Directors issued an open letter to shareholders in connection with its upcoming 2025 Annual Meeting of Shareholders, which will be held at 8:30 a.m. U.S. Eastern Time on January 23. It stated, in part, "Dear Fellow Shareholder, This year's Annual Meeting is only days away and we urge you to protect the value of your investment in Air Products by voting "FOR" ONLY Air Products' nominees on the WHITE proxy card. While Air Products successfully executes a long-term strategy for growth and value creation, Mantle Ridge continues to run a disruptive and misguided campaign focused on impeding our significant progress in favor of its own short-term goals. Support for Mantle Ridge and its insufficiently qualified and highly conflicted nominees would bring about value destruction and jeopardize Air Products' prospects."

08:21 EST Novo Nordisk drops after Ozempic selected for price U.S. negotiations - The stock is down 3%, or $2.81, to $80.26 in premarket trading.

08:18 EST TD Bank approves amendments to its Corporate Governance Guidelines - The Board has approved amendments to its Corporate Governance Guidelines to reduce the discretionary director term extension from five years to two years after an initial 10-year term. In keeping with this new policy, Amy Brinkley, Colleen Goggins and Karen Maidment will retire from the Board at the 2025 Annual Meeting of Shareholders scheduled for April 10. Claude Mongeau and Brian Ferguson have elected not to seek an extension under the new policy and will also retire at the shareholders' meeting. Other than Mr. MacGibbon, the remaining incumbent directors have joined the Board since 2020. MacGibbon has informed the Board that he will step down as Chair and retire as a director by December 31. The Corporate Governance Committee has initiated a Chair succession process. Until a new Chair is selected, MacGibbon will provide continuity as he guides the Board's renewal and supports a successful CEO transition.

08:16 EST TD Bank COO Raymond Chun to be appointed CEO on February 1 - Raymond Chun, currently COO, will be appointed Group President and CEO on February 1, accelerating the previously announced transition date of April 10. Upon Chun's appointment, Bharat Masrani will retire as Group President and CEO and from the Board of Directors. Masrani will remain available to the Bank in an advisory capacity until July 31; during the transition, he will provide continuity on the Bank's critical Anti-Money Laundering remediation effort.

08:10 EST ARway CEO acquires 3.79M shares of company stock - ARway.ai has issued the CEO of the Company an aggregate of 3,786,363 common shares at a deemed price of $0.055 per Share in satisfaction of outstanding indebtedness in the aggregate amount of $208,250. The CEO has elected to take common shares instead of cash for his salary compensation for the past few years.

08:08 EST GSI Technology selected for U.S. Army SBIR contract - GSI Technology has been selected by the U.S. Army for a potential contract award of up to $250,000 under the DoD Small Business Innovation Research program. The contract represents a significant opportunity for GSI to develop advanced, Army-specific edge computing AI solutions using its groundbreaking Gemini-II technology. First, GSI will determine the feasibility of integrating Gemini-II with AI models specifically tailored for the Army's edge computing needs. This will involve a comprehensive assessment of operational challenges, optimization with the Gemini-II architecture, and establishing key performance metrics through detailed customer discovery and technical specifications for edge AI development. The second objective centers on identifying and validating the most suitable AI algorithms for the Gemini-II platform. GSI will conduct in-depth research to select efficient edge AI models, develop a detailed integration plan, and evaluate performance metrics for low-latency and high-throughput applications of value in military environments.

08:06 EST ImmunoPrecise Antibodies realigns pipeline strategy, AI-powered pipeline - ImmunoPrecise Antibodies announced the launch of its AI-powered pipeline of both optimized and new therapeutics. By combining advanced artificial intelligence with first-principles thinking, the BioStrand pipeline reimagines drug discovery, offering unmatched speed, precision, and transparency.

08:05 EST Autonomix finalizes design of ASIC microchip for sensing technology catheter - Autonomix Medical has finalized the design, achieving "design lock", for its Application Specific Integrated Circuits microchip following the successful completion of in vivo preclinical testing and extensive bench testing, continuing progress toward its U.S. pivotal trial.

08:03 EST KB Home announces opening of community in Robla - KB Home announced the grand opening of Archer Estates in Robla, a prime Sacramento neighborhood. The one- and two-story homes at Archer Estates offer up to six bedrooms and four baths.

08:02 EST KB Home announces opening of community in Washington - KB Home announced the grand opening of Stillwater, a new community of two-story homes in desirable Lake Stevens, Washington. The community's floor plans feature up to five bedrooms and three-and-a-half baths, with some plans offering daylight basements.

08:01 EST Quantum-Si announces inducement grants under Nasdaq listing rule - Quantum-Si announced that the Compensation Committee of Quantum-Si's Board of Directors has granted 44,893 restricted stock units to new employees under the Company's previously adopted Quantum-Si Incorporated 2023 Inducement Equity Incentive Plan, as amended. The RSUs were granted as an inducement material to the new employees becoming an employee of Quantum-Si in accordance with Nasdaq Listing Rule 5635(c)(4).

07:56 EST ParaZero receives Israel MOD approval for HALO Precision Airdrop System - ParaZero Technologies has received official approval from the Israeli Defense Export Controls Agency under the Ministry of Defense for the marketing of its HALO Precision Airdrop System.

07:41 EST Brand Engagement Network prepares for 2025 Automotive AI Agent rollout - BEN is finalizing preparations to launch its Automotive AI Agent, a solution that integrates with major automotive data and service platform providers and supports over 13,000 dealerships nationwide. This initiative highlights BEN's strong commitment to the automotive sector. The AI Agent streamlines dealership operations by improving lead conversion, automating scheduling, enhancing service efficiency, and providing advanced analytics. Additionally, BEN plans to expand its efforts through pilot programs in the Midwest, stronger reseller partnerships in Mexico, and collaborations with Canadian dealership groups. These initiatives showcase BEN's dedication to delivering innovative, safe, scalable, and data-driven solutions to meet the evolving needs of automotive dealerships.

07:36 EST Quantum BioPharma to be in court with Raza Bokhari on January 24 - Quantum BioPharma (QNTM) will be back in the Ontario Superior Court of Justice on January 24, 2025. Quantum BioPharma is seeking a Court Order declaring Dr. Raza Bokhari, current CEO of Medicus Pharma, to be a vexatious litigant. Dr. Raza Bokhari was CEO of FSD Pharma (HUGE) now Quantum BioPharma, in 2019 and was terminated for cause in July 2021. As previously disclosed in Quantum BioPharma's news releases issued May 11, 2023, October 4, 2023 and February 5, 2024, Arbitrator Cunningham dismissed Dr. Bokhari's claim that the Company had wrongfully dismissed him, awarding FSD Pharma approximately C$2.81M in costs of the arbitration plus interest. Also, $175,000 in costs were awarded by Justice Conway in respect of the set aside application, and $5,000 in costs were awarded by the Court of Appeal in respect of Dr. Raza Bokhari's failed motion for leave to appeal. Dr. Raza Bokhari filed a re-consideration motion with the Court of Appeal of Ontario which is pending. Quantum BioPharma filed and served a Petition to Confirm Arbitration Award in the United States District Court for the Eastern District of Pennsylvania to formally begin the process to collect the monies awarded from Dr. Raza Bokhari. An Order was granted and Judgment was entered in favor of FSD Pharma, now Quantum BioPharma, and against respondent Dr. Raza Bokhari on June 27, 2024 as follows: 1. $147,301.04 plus interest at a rate of 4% per annum from November 9,2022, until the date the Judgment is satisfied, accruing interest of $16.14 per day; 2. C$31,912.55 plus interest at a rate of 4% per annum from November 9,2022, until the date the Judgment is satisfied, accruing interest of C$3.49 per day; 3. C$15,000, plus interest at a rate of 4% per annum from March 1, 2023,until the date the Judgment is satisfied, accruing interest of C$1.64 per day; and 4. C$2,814,229.15, plus interest at a rate of 6% per annum from May 7, 2023 until the date the Judgment is satisfied, accruing interest of $462.61 per day. Dr. Raza Bokhari also appealed this Order and Judgment and was granted stay and provided the supersedeas bond for $2,882,441.48 through the date of the issuance of the mandate by the United States Court of Appeals for the Third Circuit. Judgment by the United States Court of Appeals is pending.

07:33 EST Nextech3D.AI CEO acquires 21M shares of company stock - Nextech3D.AI has entered into an agreement with the CEO of the Company to issue an aggregate of 21,046,338 common shares at a deemed price of $0.065 per Share in satisfaction of outstanding indebtedness in the aggregate amount of $1,368,012. The CEO has elected to take common shares instead of cash for his salary compensation for the past few years.

07:31 EST Ouster announces departure of CFO Weinswig - Ouster announced the departure of its Chief Financial Officer, Mark Weinswig, effective January 31, 2025, to pursue a new career opportunity. Weinswig will assist the Company to ensure a successful transition of responsibilities prior to his departure. Weinswig's resignation is not a result of any disagreement related to the Company's operations, policies or practices, including any accounting principles and practices, or related to any financial statements or disclosures.

07:23 EST Walmart unveils new 350-acre campus in Bentonville - Walmart unveiled its New Home Office campus in Northwest Arkansas, a 350-acre designed workplace. This campus establishes a new standard for corporate headquarters that prioritizes worker well-being, environmental stewardship, and public accessibility.

07:20 EST Novo Nordisk's Semaglutide 7.2mg s.c. achieved 21% weight loss in STEP UP trial - The company states: "Novo Nordisk announced headline results from STEP UP, a phase 3b trial in the global STEP programme. STEP UP is a 72-week efficacy and safety trial investigating subcutaneous semaglutide 7.2 mg compared to semaglutide 2.4 mg and placebo, all administered once weekly. The trial included 1,407 randomised adults with obesity. All treatment arms were in conjunction with lifestyle intervention. The trial achieved its primary endpoint by demonstrating a statistically significant and superior weight loss at week 72 with semaglutide 7.2 mg versus placebo. When evaluating the effects of treatment if all people adhered to treatment1 from a mean baseline body weight of 113 kg, people treated with semaglutide 7.2 mg achieved a superior weight loss of 20.7% after 72 weeks compared to a reduction of 17.5% with semaglutide 2.4 mg and 2.4% with placebo. In addition, 33.2% of those who received semaglutide 7.2 mg achieved a weight loss of 25% or more after 72 weeks, compared to 16.7% with semaglutide 2.4 mg and 0.0% with placebo. When applying the treatment policy estimand2, people treated with semaglutide 7.2 mg achieved a superior weight loss of 18.7% compared to a reduction of 15.6% with semaglutide 2.4 mg and 3.9% with placebo. In the trial, semaglutide 7.2 mg appeared to have a safe and well-tolerated profile. The most common adverse events were gastrointestinal, and the vast majority were mild to moderate and diminished over time, consistent with the GLP-1 receptor agonist class. The results from the second semaglutide 7.2 mg phase 3 trial, STEP UP T2D, in adults with type 2 diabetes and obesity are expected within the next few months."

07:19 EST Unusual Machines adds electronic speed controller to Blue UAS Framework - Unusual Machines announced the release of the Rotor Riot Brave 55A ESC and its addition to the Blue UAS Framework. This product addresses the critical need for non-Chinese, NDAA-compliant components in the U.S. drone industry. Unusual machines now has two drone components placed on the Blue UAS Framework.

07:08 EST Grid Metals announces TSX-V approval of Makwa option, JV agreement - Grid Metals announced TSX-V approval of its definitive option and joint venture agreement with Teck Resources. Grid has also received the C$400,000 minimum cash payment that was due from Teck by January 31, 2025 as required under the Agreement.

07:05 EST SMX announces deployment of hardware protection tech for various applications - SMX announced the deployment of its proprietary hardware protection technology designed for various applications, in the rapidly evolving fields of cyber hardware and electronics, including as applied to the Artificial Intelligence industry. The company said, "Leveraging patented sub-molecular marking, and using micro-GPS trackers and advanced blockchain encryption, the SMX technology is designed to ensure unprecedented traceability and security for electronic hardware, by integrating seamlessly into manufacturing processes and to enable full authentication. This system offers: Real-Time Authentication and Control: Authorities and manufacturers can monitor, approve, identify and verify origination of sources, to mitigate risks and anti-tampering, ensuring compliance with geolocation and ownership restrictions. Blockchain-Based Digital Twin IOT2: Each marked component is paired with a tamper-proof digital twin, enabling lifecycle tracking and fraud prevention. Circular Economy Enablement: SMX's solution supports the recycling and reuse of e-waste, reducing reliance on virgin raw materials and promoting sustainability."

07:04 EST IM Cannabis announces change of auditors - IM Cannabis announces that it has changed its auditor from Kost Forer Gabbay & Kasierer, a member of Ernst & Young Global to Fahn Kanne & Co. Grant Thornton Israel, effective January 16. The Predecessor Auditor resigned effective January 16 at the company's request, and the company's board of directors, upon the audit committee's recommendation, appointed the Successor Auditor to fill the resulting vacancy until the close of the next annual meeting of the company's shareholders.

07:02 EST BioLineRx changes ratio of ADRs to ordinary shares - BioLineRx announced that its Board of Directors has approved a change in the number of its ordinary shares represented by American Depositary Shares, issued by the Bank of New York Mellon as depositary, from 15 ordinary shares per ADS to 600 ordinary shares per ADS. The change in exchange ratio for the ADSs will have the same effect as a 1-for-40 reverse stock split of the ADSs, reducing the number of outstanding ADSs from 142,340,133 to 3,558,503 ADSs. The ADSs will continue to trade on the Nasdaq Capital Market. BioLineRx's ordinary shares, which are not affected by the change, will continue to trade on the Tel Aviv Stock Exchange. The new ADS to ordinary share ratio of 1 for 600 will be effective prior to the commencement of trading on the Nasdaq Capital Market on Thursday, January 30. Because each ADS will represent 40 times the current number of BioLineRx's ordinary shares represented by ADSs and the total number of ordinary shares remains the same, the trading price of the ADSs is expected to increase by the same multiple after the ratio change, enhancing the suitability of the ADSs for trading on the Nasdaq Capital Market. BioLineRx can give no assurance, however, that the ADS price after the change in the ADS ratio will be equal to or greater than 40 times the ADS price before the change.

06:55 EST SLB sees 2025 CapEx ~$2.3B - This amount is excluding any impact from the anticipated closure of the announced acquisition of ChampionX. Capital investment for the full-year 2024 was $2.6B.

06:52 EST SLB raises quarterly dividend 3.6% to 28.5c per share - On January 16, SLB's Board of Directors approved a 3.6% increase in SLB's quarterly cash dividend from 27.5c per share of outstanding common stock to 28.5c per share, beginning with the dividend payable on April 3, to stockholders of record on February 5.

06:40 EST Citizens Financial sees Q1 NII down 1.5%-2.5%, sequentially - Sees Q1: Noninterest income down ~2% given seasonality; Non interest expense up 1.5%-2% given seasonality; Net charge-offs down moderately, continued reserve release expected; CET1 ratio 10.50%-10.75%, expects share repurchases; Tax rate 20%-21%. Comments taken from investor presentation slides.

06:33 EST Citizens Financial sees 2025 NIM up 3%-5% - Sees 2025: NIM of ~3.00%; Spot loans up low single digits driven by Private Bank and 2H25 Commercial activity; up mid single digits excluding Non-Core; Average loans down ~2%-3% reflecting 2H24 drop and continuing Non-Core run off; Interest earning assets down ~1%; Noninterest income up ~8%-10% driven primarily by Capital Markets and Wealth; Noninterest expense up ~4%; up ~2.6% ex Private Bank & Private Wealth; Net charge-off ratio ~$650M-$700M; high-40s bps; ACL likely to see releases over the course of the year; CET1 ratio 10.5%-10.75%; share repurchases dependent on market conditions and loan growth; Tax rate ~21%. Comments taken from investor presentation slides.

06:09 EST Immuron reports strong sales growth of Travelan - Sales Highlights: Global December 2024 Quarter AUD$2.5M, up 70% on prior quarter, up 249% on pcp. December 2024 Half Year AUD$4M, up 70% on pcp. Australia: December 2024 Quarter AUD$1.9M, up 83% on prior quarter, up 314% on pcp. December 2024 Half Year AUD$2.9M, up 54% on pcp. North America: December 2024 Quarter AUD$0.7M, up 43% on prior quarter, up 141% on pcp. December 2024 Half Year AUD$1.1M, up 130% on pcp.

06:05 EST Plug Power announces closing of $1.66B Energy Department loan - Plug Power last night said it closed a $1.66B loan guarantee from the U.S. Department of Energy's Loan Programs Office. "Finalizing this loan guarantee with the Department of Energy represents a significant step in the expansion of our domestic manufacturing and hydrogen production capabilities, which create many high-quality jobs throughout the U.S.," said Plug CEO Andy Marsh. "In addition to reducing carbon emissions and enhancing the resilience of the U.S. energy grid, we believe the hydrogen economy aligns closely with national security interests, ensuring that the U.S. remains at the forefront of energy technology development and deployment on a global scale." Plug says the the loan guarantee will help finance the construction of up to six projects to produce and liquify zero- or low-carbon hydrogen at scale throughout the United States.

06:01 EST 180 Degree Capital, Mount Logan Capital to merge in all-stock transaction

05:49 EST GlobalFoundries to create center for advanced packaging, testing of chips in NY - GlobalFoundries announced plans to create a new center for advanced packaging and testing of U.S.-made essential chips within its New York manufacturing facility. Supported by investments from the State of New York and the U.S. Department of Commerce, the first-of-its-kind center aims to enable semiconductors to be securely manufactured, processed, packaged and tested entirely onshore in the United States to meet the growing demand for GF's silicon photonics and other essential chips needed for critical end markets including AI, automotive, aerospace and defense, and communications. GF's overall investment in the New York Advanced Packaging and Photonics Center is expected to be $575M, with an additional $186M investment in research and development over the next 10-plus years. These efforts are expected to create approximately 100 new full-time GF jobs in New York over the next five years.

05:45 EST RBB Bancorp says no damage to properties from Southern California wildfires - RBB states, "In response to the catastrophic fires in Los Angeles County, the Bank has partnered with non-profit organizations serving low-to-moderate income communities and donated $30,000 to provide essential supplies to affected families. In addition, the company is actively reaching out to its team members and customers to perform welfare checks and is providing resources for 24/7 confidential counseling and wellness support. The company has not experienced any damage to its facilities or properties and its branches have remained open during normal business hours. Also, as of the date of this release, we are not aware of any material impact on our loan portfolio or collateral due to the Southern California wildfires. Six commercial properties with a total balance of approximately $12.5M and six residential properties with a total balance of $3.4M are near or in an evacuation area, to our knowledge, and all of such collateral has insurance coverage in place. The situation is still evolving, and we will continue to monitor its status for potential exposure. The Bank remains committed to supporting the communities it serves and is actively reviewing opportunities to make additional contributions towards recovery and the rebuilding."